LifeVantage Net Income Jumps 18% Amidst Cash Burn, Asset Decline

TL;DR

**LFVN's net income is up, but a significant cash burn and declining assets make this a risky bet; proceed with caution.**

AI Summary

LifeVantage Corp (LFVN) reported a net income of $2.155 million for the three months ended September 30, 2025, an increase of 18% from $1.826 million in the same period last year. Revenue, net, also saw a slight increase to $47.561 million, up from $47.214 million in Q1 2024. Despite the revenue growth, cash and cash equivalents decreased significantly by $7.110 million, from $20.201 million at June 30, 2025, to $13.091 million at September 30, 2025, primarily due to $2.305 million in net cash used in operating activities and $4.297 million in net cash used in financing activities. Operating income declined to $2.268 million from $2.570 million year-over-year, a 11.8% decrease, largely due to increased commissions and incentives and stable selling, general and administrative expenses. The company's total assets decreased from $71.958 million to $61.579 million, while total liabilities decreased from $37.317 million to $28.422 million. The company continues to focus on nutrigenomics and direct sales, operating in 18 countries.

Why It Matters

LifeVantage's increased net income of $2.155 million is a positive signal for investors, demonstrating profitability in a competitive direct selling market. However, the substantial $7.110 million decrease in cash and cash equivalents, driven by operating and financing activities, raises concerns about liquidity and future growth funding. This cash burn could impact the company's ability to invest in new product development or market expansion, potentially hindering its competitive position against larger health and wellness brands. Employees and independent consultants might face pressure if cash flow issues persist, affecting commission payouts or operational support. The broader market will watch if LFVN can reverse its cash outflow trend while maintaining profitability.

Risk Assessment

Risk Level: high — The company experienced a significant decrease in cash and cash equivalents by $7.110 million, from $20.201 million to $13.091 million, in just three months. This was driven by $2.305 million in net cash used in operating activities and $4.297 million in net cash used in financing activities, indicating a substantial cash outflow that is unsustainable long-term. Additionally, total assets decreased by over $10 million, from $71.958 million to $61.579 million, while operating income declined by 11.8% to $2.268 million.

Analyst Insight

Investors should closely monitor LifeVantage's next quarterly report for signs of improved cash flow from operations and a reversal in the decline of cash and cash equivalents. Consider holding off on new investments until there's clear evidence the company can generate positive cash flow and stabilize its asset base, despite the recent net income increase.

Financial Highlights

debt To Equity

0.86

revenue

$47.561M

operating Margin

4.77%

total Assets

$61.579M

total Debt

$28.422M

net Income

$2.155M

eps

$0.17

gross Margin

79.51%

cash Position

$13.091M

revenue Growth

+0.7%

Key Numbers

• $2.155M — Net Income (Increased from $1.826M in Q1 2024)
• $47.561M — Revenue, net (Slight increase from $47.214M in Q1 2024)
• $13.091M — Cash and Cash Equivalents (Decreased from $20.201M at June 30, 2025)
• $7.110M — Decrease in Cash and Cash Equivalents (Significant cash outflow during the quarter)
• $2.305M — Net Cash Used in Operating Activities (Primary driver of cash decrease)
• $4.297M — Net Cash Used in Financing Activities (Contributed to cash decrease)
• $2.268M — Operating Income (Decreased from $2.570M in Q1 2024)
• 12,701,187 — Shares Outstanding (As of November 3, 2025)
• $61.579M — Total Assets (Decreased from $71.958M at June 30, 2025)
• $28.422M — Total Liabilities (Decreased from $37.317M at June 30, 2025)

Key Players & Entities

• LifeVantage Corp (company) — Registrant
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Stock Market LLC (company) — Exchange where LFVN is registered
• Protandim (company) — Flagship product family
• TrueScience (company) — Skin and hair care product line
• Petandim (company) — Companion pet supplement
• AXIO (company) — Nootropic energy drink mixes
• Delaware (regulator) — State of incorporation
• Bloomberg (company) — Financial news outlet

FAQ

Risk Factors

• Dependence on Direct Selling Model [medium — operational]: LifeVantage operates a direct selling model, which relies heavily on independent distributors. The company's success is contingent on its ability to attract, train, and retain a sufficient number of distributors. A decline in distributor numbers or productivity could negatively impact revenue and profitability. For the three months ended September 30, 2025, commissions and incentives represented $20.695 million of operating expenses.
• Intense Competition in Health and Wellness Sector [medium — market]: The health and wellness industry is highly competitive, with numerous companies offering similar products. LifeVantage faces competition from both direct selling companies and traditional retail channels. Maintaining market share and brand differentiation requires continuous innovation and effective marketing strategies. Revenue for the quarter was $47.561 million, a modest increase from $47.214 million in the prior year.
• Regulatory Scrutiny of Direct Selling Practices [high — regulatory]: Direct selling companies are subject to scrutiny from regulatory bodies regarding their business practices, compensation plans, and product claims. Non-compliance with regulations in the 18 countries where LifeVantage operates could lead to investigations, fines, and reputational damage. The company's operating income declined by 11.8% to $2.268 million from $2.570 million year-over-year.
• Cash Flow Management and Liquidity [medium — financial]: The company experienced a significant decrease in cash and cash equivalents, falling from $20.201 million to $13.091 million during the quarter ended September 30, 2025. This was driven by $2.305 million in net cash used in operating activities and $4.297 million in financing activities, highlighting potential liquidity concerns if not managed effectively.
• International Market Expansion Challenges [medium — operational]: Operating in 18 countries presents complexities related to varying consumer preferences, economic conditions, and regulatory environments. Successful expansion requires significant investment and adaptation to local markets. The company's ability to manage these diverse operations effectively is crucial for sustained growth.

Industry Context

LifeVantage operates within the highly competitive global health and wellness market, which is characterized by a growing consumer focus on preventative health and natural products. The direct selling channel, while effective for reaching niche markets and building communities, faces increasing regulatory scrutiny and requires robust distributor engagement strategies. Key trends include the rise of personalized nutrition and the increasing demand for science-backed supplements.

Regulatory Implications

The direct selling model employed by LifeVantage is subject to stringent regulations concerning product claims, marketing practices, and compensation structures across its 18 operating countries. Potential non-compliance could lead to significant fines, legal challenges, and reputational damage, impacting investor confidence and operational continuity.

What Investors Should Do

1. Monitor cash flow trends closely.
2. Analyze the sustainability of revenue growth against rising operating costs.
3. Evaluate the company's strategy for managing distributor networks.
4. Assess the impact of international operations and regulatory environments.

Glossary

Net income per share, diluted

This metric represents the company's profit allocated to each outstanding share of common stock, assuming all convertible securities (like stock options and convertible bonds) were exercised or converted into common stock. It provides a more conservative view of profitability on a per-share basis. (For the three months ended September 30, 2025, diluted EPS was $0.17, an increase from $0.14 in the prior year, indicating improved profitability on a per-share basis despite other financial pressures.)

Accumulated deficit

This represents the cumulative net losses of a company since its inception, minus any cumulative net profits. A negative accumulated deficit indicates that the company has historically incurred more losses than profits. (LifeVantage has an accumulated deficit of ($103.141 million) as of September 30, 2025, which is a reduction from ($104.147 million) at June 30, 2025, showing a slight improvement due to recent profitability.)

Right-of-use assets

These are assets that represent a lessee's right to use an underlying asset for the lease term. They are recognized under accounting standards like ASC 842 for leases. (LifeVantage reported right-of-use assets of $7.664 million as of September 30, 2025, reflecting its obligations under various lease agreements.)

Commissions and incentives

These are payments made to sales representatives or distributors as compensation for their sales efforts. In a direct selling model, this is a significant operating expense. (Commissions and incentives were $20.695 million for the three months ended September 30, 2025, an increase from $20.305 million in the prior year, and a primary driver for the decline in operating income.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, LifeVantage reported a modest revenue increase of 0.7% to $47.561 million. However, operating income saw a notable decline of 11.8% to $2.268 million, primarily due to increased commissions and incentives. Net income rose by 18% to $2.155 million, partly aided by a lower income tax expense. Total assets and liabilities both decreased, reflecting a deleveraging and asset reduction strategy, while cash and cash equivalents experienced a significant drawdown of $7.110 million.

Key Financial Figures

• $0.0001 — b) of the Act: Common Stock, par value $0.0001 LFVN The Nasdaq Stock Market LLC Title

Filing Documents

• lfvn-20250930.htm (10-Q) — 747KB
• lfvn_93025xex311.htm (EX-31.1) — 9KB
• lfvn_93025xex312.htm (EX-31.2) — 9KB
• lfvn_93025xex321.htm (EX-32.1) — 5KB
• lfvn_93025xex322.htm (EX-32.2) — 5KB
• 0001628280-25-048792.txt ( ) — 4449KB
• lfvn-20250930.xsd (EX-101.SCH) — 28KB
• lfvn-20250930_cal.xml (EX-101.CAL) — 57KB
• lfvn-20250930_def.xml (EX-101.DEF) — 104KB
• lfvn-20250930_lab.xml (EX-101.LAB) — 472KB
• lfvn-20250930_pre.xml (EX-101.PRE) — 294KB
• lfvn-20250930_htm.xml (XML) — 444KB

Financial Information

PART I. Financial Information 5

Financial Statements

Item 1. Financial Statements: 5 Condensed Consolidated Balance Sheets (unaudited) 5 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) 6 Condensed Consolidated Statement of Stockholders' Equity (unaudited) 7 Condensed Consolidated Statements of Cash Flows (unaudited) 9 Notes to Condensed Consolidated Financial Statements (unaudited) 10

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 20

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 27

Controls and Procedures

Item 4. Controls and Procedures 27

Other Information

PART II. Other Information 27

Legal Proceedings

Item 1. Legal Proceedings 27

Risk Factors

Item 1A. Risk Factors 27

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 28

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 28

Other Information

Item 5. Other Information 28

Exhibits

Item 6. Exhibits 29

Financial Information

PART I. Financial Information

Financial Statements

Item 1. Financial Statements LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2025 June 30, 2025 (In thousands, except per share data) ASSETS Current assets Cash and cash equivalents $ 13,091 $ 20,201 Accounts receivable 2,425 3,294 Income tax receivable 5,298 635 Inventory, net 20,594 20,669 Prepaid expenses and other 3,640 6,095 Total current assets 45,048 50,894 Property and equipment, net 5,997 6,207 Right-of-use assets 7,664 8,041 Intangible assets, net 245 245 Deferred income tax asset 1,989 5,970 Other long-term assets 636 601 TOTAL ASSETS $ 61,579 $ 71,958 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 4,356 $ 4,600 Commissions payable 5,986 7,237 Income tax payable — — Lease liabilities 1,881 1,867 Other accrued expenses 6,606 13,513 Total current liabilities 18,829 27,217 Long-term lease liabilities 9,310 9,811 Other long-term liabilities 283 289 Total liabilities 28,422 37,317 Commitments and contingencies - Note 7 Stockholders' equity Preferred stock — par value $ 0.0001 per share, 5,000 shares authorized, no shares issued or outstanding — — Common stock — par value $ 0.0001 per share, 40,000 shares authorized and 12,691 and 12,429 issued and outstanding as of September 30, 2025 and June 30, 2025, respectively 1 1 Additional paid-in capital 137,652 139,962 Accumulated deficit ( 103,141 ) ( 104,147 ) Accumulated other comprehensive loss ( 1,355 ) ( 1,175 ) Total stockholders' equity 33,157 34,641 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 61,579 $ 71,958 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) Three Months Ended September 30, 2025 2024 (In thousands, except per share data) Revenue, net $ 47,561 $ 47,214 Cost of sales 9,745 9,49

View Full Filing

View this 10-Q filing on SEC EDGAR